ICU patients may need custom doses of common antifungal drug
NCT ID NCT02164890
First seen Nov 21, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study looked at how the antifungal drug micafungin behaves in critically ill ICU patients with invasive candidiasis, a serious fungal infection. Researchers measured drug levels in 60 patients to see if standard doses are enough or if personalized dosing is needed. The goal was to improve treatment success by ensuring patients get the right amount of medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Montpellier
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.